department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Febuxostat · pharmadog

pharmadog
drugs
Febuxostat

drug

patient view →

febuxostat

Marketedupdated 2mo ago

by Novadoz Pharmaceuticals LLC

Approved

community read0 votes

all catalysts(1)

phase 1 initiation · 1

phase 1 initiation

Bio-Innova Co Ltd — febuxostat (Phase I Trial Initiation)

News(0)

no news has mentioned this drug yet

brand

Febuxostat

generic

febuxostat

indication

Hyperuricemia

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 32m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 8, 2031

~5.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Sep 8, 2031method-of-use (U-1346)US 8372872
Sep 8, 2031method-of-use (U-1346)US 8372872
Sep 8, 2031method-of-use (U-1346)US 9107912
Sep 8, 2031method-of-use (U-1346)US 9107912

🐶 often sniffed alongside

top 3

companyBio-Innova Co Ltd1 co-mentions · 1 sources
tagEndocrinology & Metabolism1 co-mentions · 1 sources
tagOrthopedics1 co-mentions · 1 sources

Trials studying febuxostat

phase3A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patientscompletedn=612
phase2Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemianot yet recruitingn=80
phase2The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemiarecruitingn=340
phase2Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemianot yet recruitingn=160
phase3Tigulixostat (IBI128) vs Febuxostat in Goutrecruitingn=600
phase2Boosting Osimertinib Blood Brain Barrier Penetrationnot yet recruitingn=7
phase3Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adultscompletedn=765
phase1Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjectsnot yet recruitingn=48

more trials →